Plain-English translation of NCT06583070 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether combining a type of precise radiation therapy called SABR (stereotactic ablative radiotherapy) with targeted therapy and anti-PD-1 immunotherapy can help patients with kidney cancer that has recurred or metastasized. The study compares two groups: one that receives the medication plus radiation to visible tumors, and one that receives the medication alone. Early research suggests this combination may help people stay cancer-free longer.
When kidney cancer comes back or spreads, patients typically only survive 1–2 years after starting treatment. The researchers believe that adding precise radiation to destroy visible tumors, combined with the medication that fights cancer throughout the body, may improve how long people survive and how well they do.
You likely qualify if…
You likely don't qualify if…
If you are assigned to the treatment group, you will receive the medication along with radiation therapy aimed at all visible tumors. If you are in the control group, you will receive the medication alone. You will have regular visits to your medical team for imaging scans, blood tests, and check-ups to see how you're doing and whether the cancer is responding to treatment. The study will follow you for an extended period to measure how long you stay cancer-free and to monitor for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China